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Background: Sister Mary Joseph’s nodule is a metastatic tumor deposit in the umbilicus and often represents
advanced intra-abdominal malignancy with dismal prognosis. There is a paucity of published data on this subject in
our setting. This study was conducted to describe the clinicopathological presentation and treatment outcome of
this condition in our environment and highlight challenges associated with the care of these patients, and to
proffer solutions for improved outcome.
Methods: This was a retrospective study of histologically confirmed cases of Sister Mary Joseph’s nodule seen at
Bugando Medical Centre between March 2003 and February 2013. Data collected were analyzed using descriptive
statistics.
Results: A total of 34 patients were enrolled in the study. Males outnumbered females by a ratio of 1.4:1. The vast
majority of patients (70.6%) presented with large umbilical nodule > 2 cm in size. The stomach (41.1%) was the
most common location of the primary tumor. Adenocarcinoma (88.2%) was the most frequent histopathological
type. Most of the primary tumors (52.9%) were poorly differentiated. As the disease was advanced and metastatic in
all patients, only palliative therapy was offered. Out of 34 patients, 11 patients died in the hospital giving a mortality
rate of 32.4%. Patients were followed up for 24 months. At the end of the follow-up period, 14(60.9%) patients were
lost to follow-up and the remaining 9 (39.1%) patients died. Patients survived for a median period of 28 weeks
(range, 2 to 64 weeks). The nodule recurred in 6 (26.1%) patients after complete excision.
Conclusion: Sister Mary Joseph’s nodule of the umbilicus is not rare in our environment and often represents
manifestation of a variety of advanced intra-abdominal malignancies. The majority of the patients present at a late
stage and many with distant metastases. The patient's survival is very short leading to a poor outcome. Early
detection of primary cancer at an early stage may improve the prognosis.
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Sister Mary Joseph’s nodule is a metastatic tumor de-
posit in the umbilicus and often represents advanced
intra-abdominal malignancy with dismal prognosis [1].
The term “Sister Mary Joseph’s nodule” was coined by Sir
Hamilton Bailey in his book, Physical Signs in Clinical
Surgery, in honor of Sister Mary Joseph, Dr. William
Mayo’s surgical assistant in the early days of the Mayo* Correspondence: drphillipoleo@yahoo.com
1Department of Surgery, Catholic University of Health and Allied Sciences-
Bugando, Mwanza, Tanzania
Full list of author information is available at the end of the article
© 2013 Chalya et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orClinic. Sister Mary Joseph identified the relationship be-
tween umbilical nodules and advanced intra-abdominal
malignancy [2-4].
Sister Mary Joseph’s nodules are usually malignant and
the most common primary site is an abdomino-pelvic
tumor. It is estimated that 1 to 3% of the abdomino-pelvic
malignancies metastasize to the umbilicus [5-7]. In men,
the commonest primary site is the gastro-intestinal tract
of which the stomach is the single most common entity,
whereas gynecological malignancies – particularly epithe-
lial ovarian tumors – are the most common primary sites
in women. In 15 to 30% of patients, the source of theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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mon histological type is adenocarcinoma (75%), more
rarely squamous cell carcinoma, followed by undifferenti-
ated tumors or carcinoids that can metastasize to the
umbilicus [11-14]. Sometimes umbilical nodules may be
benign (for example, endometriosis, fibroma, epithelial in-
clusion cysts, foreign body granuloma, keloid, myxoma),
and occasionally it may be a primary malignant tumor of
the umbilicus (for example, melanoma, squamous or basal
cell carcinoma, sarcoma) [15]. Benign umbilical nodules
are called Pseudo Sister Mary Joseph’s nodules [16].
Therefore, a histological or cytological study of the umbi-
licus is not only mandatory, but it also guides the clinician
to search for the potential primary site.
The presence of an umbilical metastasis indicates a poor
prognosis and is a sign of advanced malignant disease.
The survival of these patients has been reported to range
from 2 to 11 months from the time of initial diagnosis
[2,6,11,17,18]. Because Sister Mary Joseph’s nodule may
sometimes be the first and only sign of an internal neo-
plasm and prognosis is mostly poor, diagnosis has to be
confirmed in the early stages to improve average survival.
The diagnosis of Sister Mary Joseph’s nodule is usually
delayed due to non-specific symptoms that are often
misinterpreted as benign umbilical nodules. The lack of
suspicion and general reluctance to perform invasive
investigations contributes to late diagnosis. The delay in
diagnosis and, consequently, treatment leads to the ex-
tremely poor prognosis associated with this disease. A
high index of suspicion is required in the management
of Sister Mary Joseph’s nodule and all suspected lesions
should be biopsied.
The management of Sister Mary Joseph’s nodule in
resource-limited countries like Tanzania poses major
therapeutic challenges which need to be addressed. Late
presentation with advanced lesions coupled with a lack
of therapeutic facilities such as adjuvant therapy services
are among the hallmarks of the disease in developing
countries. The outcome of patients with Sister Mary
Joseph’s nodule has been poor because the majority of
these patients present late to the hospital with advanced
stage. This is partly due to paucity of local data regar-
ding this condition and lack of community awareness on
the importance of early reporting to hospital for early
diagnosis and treatment. This study was conducted to
describe the clinicopathological pattern and treatment
outcome of patients with Sister Mary Joseph’s nodule
treated at our center and to highlight challenges associated
with the care of these patients and proffer solutions for
improved outcome.
Methods
Between March 2003 and February 2013, a retrospective
study of histologically confirmed cases of Sister MaryJoseph’s nodule was conducted at Bugando Medical Cen-
ter. Bugando Medical Center is a tertiary care and teach-
ing hospital for the Catholic University of Health and
Allied Sciences-Bugando (CUHAS-Bugando) in the Lake
and Western Zones of the United Republic of Tanzania. It
is situated along the shores of Lake Victoria in Mwanza
City. It has 1000 beds and serves as a referral center for
tertiary specialist care for a catchment population of
approximately 13 million people. The hospital has a newly
established oncology department which provides care for
all patients with histopathologically proven cancers. How-
ever, the department does not provide radiotherapy
services at the moment due to the lack of this facility at
our center. As a result, patients requiring this modality of
treatment have to travel long distances to receive radio-
therapy at the Tanzania Tumor Center, located a conside-
rable distance from the study area.
The study population included all patients who
presented to Bugando Medical Center with histologically
confirmed Sister Mary Joseph’s nodule during the study
period. Patients with incomplete data were excluded
from the study.
The details of patients were retrieved from the patient
files kept in the medical record department, the surgical
wards, operating theatre and histopathology laboratory.
The data collected included age, gender, clinical presen-
tation, size of umbilical nodules, timing of discovery of
nodules, investigations carried out to look for the primary
cancer, sites of origin of primary cancer, therapeutic
options, and duration of survival. The diagnosis of Sister
Mary Joseph’s nodule was confirmed in all patients by
umbilical biopsy, and a histopathological review showed
various malignancies metastasizing to the umbilicus.
Searching for the primary cancer was aided by gastrointes-
tinal endoscopies (that is,oesophagogastroduodenoscopy)
and imaging modalities (that is, abdominal ultrasound,
computed tomography (CT) scan and barium studies).
Advanced diagnostic investigation such as magnetic res-
onance imaging (MRI), endoscopic retrograde cho-
langiopancreatography (ERCP), percutaneous transhepatic
cholangiopancreatography (PTC), positron emission to-
mography (PET) and a panel of tumor markers was not
done in any of our patients as these facilities are not
available at our center. Patients were followed up in the
Surgical Outpatient Department and their death and
recurrence of the disease was documented.Statistical data analysis
Statistical data analysis was performed using SPSS com-
puter software version 17.0 (SPSS, Inc., Chicago, IL, USA).
Data were summarized in the form of proportions and
frequency tables for categorical variables. Continuous vari-
ables were summarized using median and ranges.
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Results
During the study period, a total of 34 patients were en-
rolled in the study. There were 20 (58.8%) males and 14
(41.2%) females with a male to female ratio of 1.4:1. The
age of patients at presentation ranged from 19 to 73 years
with a median age of 46 years. The modal age group was
41–50 years (Figure 1). The vast majority of patients (28,
82.4%) came from the rural areas located a considerable
distance from Mwanza City and most of them (30,88.2%)
had either primary or no formal education.
The duration of illness ranged from 1 to 6 months
with a median of 3 months and the majority of patients
(25,73.5%) presented between 2 and 4 months of onset
of illness. Table 1 shows the distribution of patients
according to clinical presentation. All patients presented
with umbilical nodules. The nodules were discovered at
the initial clinical examination in 26 (76.5%) patients
and in the other 8 (23.5%) patients it was noticed during
surgery. The umbilical nodules were tender and ulcer-
ated in 20 (58.8%) patients, hard in all, and the median
nodule size at presentation was 3cm (range 2 to 5 cm).
The vast majority of patients (70.6%) presented with a
large nodule, >2 cm in size. One patient with an umbi-
lical nodule reported an operation for colonic cancer 3
years previously. The stomach was the most commonFigure 1 Distribution of patients according to age group.location of the primary tumor, accounting for 41.1% of
cases. Adenocarcinoma was the most frequent histo-
pathological type occurring in 88.2% of patients. Most of
the primary tumors (52.9%) were poorly differentiated
(Table 2).
Surgical intervention with or without adjuvant therapy
was performed in 28 (82.4%) patients. The remaining 6
(17.6%) patients were unfit for surgery and only an inci-
sional biopsy from the umbilical nodule was taken to
confirm the diagnosis. Table 3 shows the type of surgical
procedure performed. Chemotherapy was given to only
5 (14.7%) patients who had non-Hodgkin lymphoma,
colonic and ovarian carcinoma. Only 1 patient (2.9%)
who had squamous cell carcinoma was referred to the
Ocean Road Cancer Institute for possible radiotherapy.
However, due to final constraints this patient could not
get access to this form of treatment and they were lost
to follow-up.
Out of 34 patients, 11 patients died in the hospital gi-
ving a mortality rate of 32.4%. The remaining survivors
(23 patients) were followed-up the Surgical Outpatient
Department for a period of 24 months. Follow-up of
patients among survivors ranged from 3 to 24 months
with a median of 8 months. At the end of the follow-up
period, 14 (60.9%) patients were lost to follow-up and
the remaining 9 (39.1%) patients died and their date of
death was obtained from relatives. The patients survived
for only a few weeks after clinical presentation with
Sister Mary Joseph’s nodule. They survived for a median
period of 28 weeks (range, 2 to 64 weeks). The nodule
recurred in 6 (26.1%) patients after complete excision.
Table 1 Distribution of patients according to clinical
presentation
Clinical presentation Frequency Percentage
Abdominal pain 30 88.2
Abdominal mass 26 76.5




Rectal bleeding 4 11.7
Hematemesis/ melena 1 2.9
Other rare symptoms 6 17.6
Table 3 Distribution of patients according to the type of
surgical procedure performed (N= 28)
Type of surgical procedure performed Frequency Percentage
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Sister Mary Joseph’s nodule refers to a palpable nodule
bulging into the umbilicus as a result of metastasis of a
malignant cancer in the pelvis or abdomen [1,5,6]. Sir
Hamilton Bailey first described the term “Sister Mary
Joseph’s nodule” in 1949 in honor of Sister Mary Joseph
who was a nurse superintendent and a surgical assistant
of Dr William Mayo at St Mary's Hospital (presently the
Mayo Clinic) in Rochester Minnesota, USA from 1890
to 1915. Sister Mary Joseph was the first to note the linkTable 2 Distribution of patients according to nodule size,
primary tumor location, histopathological type and
tumor grade
Study variables Frequency Percentage
Umbilical nodule size
• ≤2 cm 10 29.4
• >2cm 24 70.6
Primary tumor site
• Stomach 14 41.2
• Colorectum 3 8.8
• Pancreas 2 5.9
• Ovary 2 5.9
• Gall bladder 1 2.9
• Anus 1 2.9
• Unknown 11 32.4
Histopathological type
• Adenocarcinoma 30 88.2
• Non-Hodgkin's lymphoma 1 2.9
• Squamous cell carcinoma 1 2.9
• Anaplastic carcinoma 1 2.9
• Cholangiocarcinoma 1 2.9
Tumor differentiation
• Well differentiated 5 14.7
• Moderately differentiated 6 17.6
• Poorly differentiated 18 52.9
• Not documented 5 14.7between umbilical nodules and intra-abdominal malig-
nancy [2-4]. Since then, more than 400 cases of Sister
Mary Joseph's nodule have been described in the litera-
ture [17]. It is estimated that 1 to 3% of patients with
abdomino-pelvic malignancy could present with a Sister
Mary Joseph’s nodule [5-7].
In this review, the median age of patients at presentation
was 46 years, which is lower than the age reported in the
literature [6,19]. A study performed in India by Al-Mashat
and Sibiany [19] reported the mean age of patients at diag-
nosis to be 50.6 years (range, 18–87 years). Other studies
reported older age at presentation [19,20]. We could not
establish the reason for this age difference.
Epidemiological studies revealed that Sister Mary
Joseph's nodule predominates in women [20,21]. This
observation is at variant with our findings in the present
study which showed male predominance. The reason for
this gender difference remains unclear.
The gastrointestinal tract is the most common location
of the primary neoplasm (35 to 65%), followed by a
gynecological origin (12 to 35%) [1]. The common sites
in decreasing order of frequency are: stomach (25%),
colorectal (10%), and pancreas (7%) [1,19]. In females,
ovarian cancer is the most common primary site, of
which serous papillary cystadenocarcinoma is the most
frequent (34%) [1,11]. As reported in the literature [11],
the stomach was the most common primary site in this
study. Primary tumors in many other sites have been
reported to lead to Sister Mary Joseph's nodule, including
gallbladder, liver, breast, lung, prostate, penis, peritoneum,
lymphoma, bladder, kidney, endometrium, cervix, vagina,
vulva, and fallopian tube [11,19]. In 15 to 30% of the cases,
the source of the primary site of the tumor is unknown
[8-10]. This finding concurs with our study in which the
primary site was not known in 29.4% of cases.
Sister Mary Joseph's nodule can be the first manifest-
ation of an underlying malignancy or an indication of a re-
currence in a patient with a previous malignancy [22]. In
the present study, 1 patient developed metastatic umbi-
lical nodule 3 years after laparotomy for colonic cancer.
Al-Mashatand Sibiany [19] reported 1 patient who deve-
loped Sister Mary Joseph's nodule 3 years after laparo-
scopic cholecystectomy. Direct implantation following
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other mode of spread of intra-abdominal tumors to the
umbilicus [23].
The majority of patients in this study presented late with
advanced stage of cancer which is in keeping with other
studies performed in developing countries [19,22]. Late
presentation in our study may be attributed to lack of
awareness of the disease, a low standard of education, a
lack of accessibility to healthcare facilities, and a lack of
advanced diagnostic investigations such as MRI and PET
and a panel of tumor markers in this region. Late presen-
tation of cases is an area of cancer care in our center that
requires urgent attention. Detecting primary cancer at an
early stage contributes to improved chances for successful
treatment and thus for survival.
The potential differential diagnosis to be considered
when evaluating a patient with Sister Mary Joseph's nodule
includes benign causes such as endometriosis, melanocytic
nevi, fibroepithelialpapillomas, dermatofibroma, fibroma,
epithelial inclusion cyst, urachal duct cyst, seborrheic
keratosis, pilonidal sinus, keloid, foreign body, granuloma,
myxoma, omphalitis, polyp, abscess, and umbilical hernia
[5,11,24]. Additional differential diagnosis includes pri-
mary malignant umbilical tumors, which are exceedingly
rare, accounting for 17% of the cases and including mela-
nomas, basal cell carcinomas, squamous cell carcinomas,
myosarcomas, and adenocarcinomas [5,11].
The spread of metastatic cancer to the umbilical region
has been postulated to occur in several ways. These in-
clude direct extension from a contiguous tumor (the most
important), hematogenous (arterial and venous), lymph-
atic and direct extension along the vestigial remnants of
embryonal ligaments including the round ligament, the
urachus, the vitellointestinal duct remnant, and the obli-
terated vitelline artery [24-26]. In addition, direct implan-
tation following laparoscopy is another mode of spread of
tumors to the umbilicus [23].
Patients with Sister Mary Joseph's nodule often present
with a painful lump with irregular margins and hard
consistency. The surface may be ulcerated and necrotic
with either blood, serous, purulent, or mucous discharge
from it. The size of the nodule usually ranges from 0.5 to
2 cm, although some nodules may reach up to 10 cm in
size [1,6]. The median size of the nodule in our study was
3 cm and the vast majority of patients (82.4%) presented
with large nodule >2 cm in size and more than 70% of
nodules were ulcerated.
Various imaging modalities can aid in establishing the
diagnosis, such as ultrasonography, CT, MRI, and PET.
Once Sister Mary Joseph's nodule is discovered, a biopsy –
either excisional or fine needle aspiration cytology – is
mandatory to establish diagnosis and to find the possible
primary site. The histopathological evaluation may show
characteristics of the underlying tumor, or they may havea more anaplastic appearance. In the situation of an ana-
plastic tumor, immunohistochemical marker studies and
ultrastructural examination may help delineate the tissue
of origin [27]. In the present study, the diagnosis of pri-
mary cancer was performed by gastrointestinal endosco-
pies (that is,oesophagogastroduodenoscopy) and imaging
modalities (that is, abdominal ultrasound, CT scan and
barium studies) and histopathological examination of the
biopsy specimen was performed to confirm the diagnosis.
Advanced diagnostic investigation such as MRI, ERCP,
PTC, PET and a panel of tumor markers was not
performed in any of our patients as these facilities are not
available at our center.
The most common histopathological type in our pa-
tients was adenocarcinoma, accounting for 88.2% of cases,
which is consistent with that reported in the literature
[11,19]. Other histopathological types include non-
Hodgkin's lymphoma, squamous cell carcinoma, anaplas-
tic carcinoma and cholangiocarcinomawhich is similar to
the worldwide experience [11-14,19]. More than 50% of
tumors in this study were poorly differentiated.
The presence of Sister Mary Joseph's nodules usually
signifies an advanced, metastasizing cancer and, therefore,
a poor prognosis. The finding of a metastatic nodule at
the umbilical site almost certainly establishes the inope-
rability of the patient [28]. This conclusion was disputed
by others who believe that the existence of Sister Mary
Joseph's nodule is insufficient proof of widespread meta-
static disease that would prevent an operation. Uncom-
monly, Sister Mary Joseph's nodule may represent a
solitary metastasis or possibly a primary tumor that has
not yet metastasized [29,30].
Sister Mary Joseph's nodule usually represents wide-
spread metastasis and treatment is commonly palliative.
Several authors have advocated wide excision with exten-
sive search for the primary lesion [30,31], radiotherapy
[32], and surgery with adjuvant therapy [26]. Majmudar
and colleagues [26] have shown that patients treated
aggressively with both surgery and adjuvant therapy live
for an average of 17.6 months, which is more than with
surgery alone (7.4 months), adjuvant therapy alone (10.3
months), or no treatment (2.3 months). An aggressive sur-
gical approach combined with chemotherapy may improve
survival [1]. In our series, surgical interventions were of a
palliative nature, without curative intent, as all patients
had either locally advanced or metastatic disease. Wide
nodule excision and gastro-jejunostomy were the most
frequent surgical procedure performed in this study. Adju-
vant chemotherapy was given to only 14.7% of cases.
Sister Mary Joseph's nodule has traditionally been consi-
dered a sign of advanced primary malignancy with an asso-
ciated poor prognosis; the average survival time has been
reported to be 11 months with <15% of the patients survi-
ving >2 years [19]. In some patients, however, depending on
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condition, surgery and/or chemotherapy may improve sur-
vival [1]. In agreement with other studies [19,22], our pa-
tients survived for a median period of 28 weeks. This very
short survival is in keeping with the advanced and meta-
static nature of the primary cancer.
The potential limitation of this study is the fact that
information about some patients was incomplete in view
of the retrospective nature of the study and this might
have introduced some bias in our findings.
Conclusion
Sister Mary Joseph’s nodule of the umbilicus is not rare in
our environment and often represents manifestation of a
variety of advanced intra-abdominal malignancies. The ma-
jority of the patients present at a late stage with advanced
disease. The patient's survival is very short leading to a poor
outcome. We believe that if the primary cancer is detected
at an early stage, the prognosis may improve. A careful
examination of all umbilical lesions is recommended, espe-
cially in those patients with gastrointestinal and genitouri-
nary tract malignancies. All umbilical mass lesions should
be biopsied to determine the pathological nature of the le-
sion. An aggressive surgical approach combined with
chemotherapy treatment may be considered to offer the
patient the best survival probability.
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